MiMedx Group, Inc (NASDAQ:MDXG) Receives Average Recommendation of “Moderate Buy” from Brokerages

MiMedx Group, Inc (NASDAQ:MDXG) has received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $8.5714.

MDXG has been the topic of several recent research reports. Craig Hallum upped their price target on MiMedx Group from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Raymond James Financial set a $8.00 price objective on MiMedx Group in a research report on Monday, August 17th. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 target price on shares of MiMedx Group in a report on Monday, August 17th. Wall Street Zen raised shares of MiMedx Group from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. Finally, Weiss Ratings upgraded shares of MiMedx Group from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, August 27th.

Institutional Investors Weigh In On MiMedx Group

A number of hedge funds and other institutional investors have recently bought and sold shares of MDXG. Sunbelt Securities Inc. bought a new position in shares of MiMedx Group during the first quarter valued at approximately $42,000. E Fund Management Co. Ltd. purchased a new stake in MiMedx Group during the 2nd quarter valued at about $45,000. Syon Capital LLC purchased a new stake in shares of MiMedx Group during the second quarter valued at approximately $45,000. Legal & General Group Plc purchased a new stake in MiMedx Group during the 2nd quarter valued at $45,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of MiMedx Group during the fourth quarter valued at $48,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Performance

Shares of MDXG opened at $4.60 on Friday. The company has a 50-day simple moving average of $4.31 and a two-hundred day simple moving average of $4.05. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79. The firm has a market capitalization of $670.50 million, a PE ratio of 115.03 and a beta of 1.43. MiMedx Group has a one year low of $3.03 and a one year high of $7.97.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). The firm had revenue of $64.36 million for the quarter, compared to the consensus estimate of $63.46 million. MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%. On average, analysts anticipate that MiMedx Group will post -0.1 EPS for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.